LongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds

Bulletin Express06-30

LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares at HK$96.06 per share. The transaction, executed on 30 June 2026 by the sole sponsor-overall coordinator on behalf of the international underwriters, increases the total H shares issued under the offering from 14.19 million to 16.32 million.

Following settlement, LongBio Pharma’s total share capital will rise from 74.19 million shares to 76.32 million shares. The proportion of H shares in issue expands from 19.13% to 21.39%, while unlisted shares remain at 1.26 million, now representing 1.65% of the enlarged share base. H shares converted from unlisted shares stand unchanged at 58.74 million, accounting for 76.96% of total share capital post-exercise.

The fully exercised greenshoe is expected to generate net proceeds of approximately HK$194.30 million after deducting underwriting commissions and related expenses. The company will allocate these funds on a pro-rata basis in line with the “Future Plans and Use of Proceeds” section detailed in its prospectus.

The Hong Kong Stock Exchange has granted approval for the listing of the additional shares, with trading set to commence on the Main Board at 9:00 a.m. on 6 July 2026. LongBio Pharma confirmed that it will continue to meet the public float requirements prescribed under Rule 19A.28B(1) of the Listing Rules. A further announcement will be issued after the conclusion of the stabilization period for the global offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126218520?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126218520","market":"hk","top_or_hot":-1,"title":"LongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds","media":"Bulletin Express","content":"<p>LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares at HK$96.06 per share. The transaction, executed on 30 June 2026 by the sole sponsor-overall coordinator on behalf of the international underwriters, increases the total H shares issued under the offering from 14.19 million to 16.32 million.</p>\n<p>Following settlement, LongBio Pharma’s total share capital will rise from 74.19 million shares to 76.32 million shares. The proportion of H shares in issue expands from 19.13% to 21.39%, while unlisted shares remain at 1.26 million, now representing 1.65% of the enlarged share base. H shares converted from unlisted shares stand unchanged at 58.74 million, accounting for 76.96% of total share capital post-exercise.</p>\n<p>The fully exercised greenshoe is expected to generate net proceeds of approximately HK$194.30 million after deducting underwriting commissions and related expenses. The company will allocate these funds on a pro-rata basis in line with the “Future Plans and Use of Proceeds” section detailed in its prospectus.</p>\n<p>The Hong Kong Stock Exchange has granted approval for the listing of the additional shares, with trading set to commence on the Main Board at 9:00 a.m. on 6 July 2026. LongBio Pharma confirmed that it will continue to meet the public float requirements prescribed under Rule 19A.28B(1) of the Listing Rules. A further announcement will be issued after the conclusion of the stabilization period for the global offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-30 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares at HK$96.06 per share. The transaction, executed on 30 June 2026 by the sole sponsor-overall coordinator on behalf of the international underwriters, increases the total H shares issued under the offering from 14.19 million to 16.32 million.</p>\n<p>Following settlement, LongBio Pharma’s total share capital will rise from 74.19 million shares to 76.32 million shares. The proportion of H shares in issue expands from 19.13% to 21.39%, while unlisted shares remain at 1.26 million, now representing 1.65% of the enlarged share base. H shares converted from unlisted shares stand unchanged at 58.74 million, accounting for 76.96% of total share capital post-exercise.</p>\n<p>The fully exercised greenshoe is expected to generate net proceeds of approximately HK$194.30 million after deducting underwriting commissions and related expenses. The company will allocate these funds on a pro-rata basis in line with the “Future Plans and Use of Proceeds” section detailed in its prospectus.</p>\n<p>The Hong Kong Stock Exchange has granted approval for the listing of the additional shares, with trading set to commence on the Main Board at 9:00 a.m. on 6 July 2026. LongBio Pharma confirmed that it will continue to meet the public float requirements prescribed under Rule 19A.28B(1) of the Listing Rules. A further announcement will be issued after the conclusion of the stabilization period for the global offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1126218520","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126218520","pubTimestamp":1782830577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"龙生制药全数行使15%超额配股权，获得额外所得款项194,300,000港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares at HK$96.06 per share. The transaction, executed on 30 June 2026 by the sole sponsor-overall coordinator on behalf of the international underwriters, increases the total H shares issued under the offering from 14.19 million to 16.32 million.\nFollowing settlement, LongBio Pharma’s total share capital will rise from 74.19 million shares to 76.32 million shares. The proportion of H shares in issue expands from 19.13% to 21.39%, while unlisted shares remain at 1.26 million, now representing 1.65% of the enlarged share base. H shares converted from unlisted shares stand unchanged at 58.74 million, accounting for 76.96% of total share capital post-exercise.\nThe fully exercised greenshoe is expected to generate net proceeds of approximately HK$194.30 million after deducting underwriting commissions and related expenses. The company will allocate these funds on a pro-rata basis in line with the “Future Plans and Use of Proceeds” section detailed in its prospectus.\nThe Hong Kong Stock Exchange has granted approval for the listing of the additional shares, with trading set to commence on the Main Board at 9:00 a.m. on 6 July 2026. LongBio Pharma confirmed that it will continue to meet the public float requirements prescribed under Rule 19A.28B(1) of the Listing Rules. A further announcement will be issued after the conclusion of the stabilization period for the global offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126218520","isCrawlerRequest":true}